Anti-HCV Next— 510(k) K252424
Substantially EquivalentAbbott Laboratories
FDA 510(k) clearance K252424 for Anti-HCV Next, Substantially Equivalent on 2026-04-28. Applicant: Abbott Laboratories.
Clearance details
- Applicant
- Abbott Laboratories
- Product code
- Code MZO
- Advisory panel
- Microbiology
- Date received
- Decision date
- Decision
- Substantially Equivalent
- Clearance type
- Traditional
- Location
- Abbott Park, IL, US
Adverse events under product code MZO
product code MZO- Malfunction
- 466
- Total
- 466
Source: openFDA MAUDE database, through . Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →
Data sourced from openFDA. This site is unofficial and independent of the FDA.